Inovio Pharma (INO) Misses Q4 EPS by $1.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Inovio Pharmaceuticals (INO) PT Lowered to $30 at Oppenheimer
March 2, 2022 12:56 PM ESTOppenheimer analyst Hartaj Singh lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $30.00 (from $35.00) while maintaining an Outperform rating after the company provided a business and pipeline update to investors on 3/1.
The analyst commented, "While the company reported steady progress, the... More
